|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Non-Insulin Antidiabetics - Type 2 Diabetes Unlikely To Develop Into a Switch Market
Datamonitor, Aug 2006, Pages: 237
We expect the continuously growing prevalence of diabetes to drive growth in diabetes drug spending, benefiting market uptake of newly developed, efficacious therapies. A variety of novel, non-insulin antidiabetic agents are poised to become available to patients in the next decade, with two DPP-4 inhibitors likely to launch in 2007 and two GLP-1 agonists entering the market by 2010.
Scope of this title:
-Assessment of the patient potential for developmental non-insulin agents in the type 2 diabetes setting of over the period 2006-15
-Overview of the non-insulin antidiabetics R&D pipeline, with detailed information on the classes in development and comparator drugs
-Commercial analysis of key compounds in development regarding their ability to satisfy key unmet needs, supported by the views of key opinion leaders
-Sales forecasts for key late-stage developmental non-insulin antidiabetics in the seven major markets to 2015
Highlights of this title:
The diabetes market is worthy of investment because of the endemic size of its patient pool which is set to grow further, and the nature of its unmet clinical needs. This situation is reflected in the R&D pipeline for non-insulin antidiabetics, comprising a diverse collection of 76 novel agents in clinical development.
We have identified five late-stage candidate drugs likely to be launched in the diabetes market within the next five years. These are the DPP-4 inhibitors Galvus and Januvia, the GLP-1 agonists Byetta LAR and liraglutide, the PPAR-gamma modulator metaglidasen. Apart from metaglidasen, all four agents have blockbuster potential.
Despite the fact that pipeline products will impact the diabetes market greatly in the next five years, there are currently no agents in late-stage clinical development that are likely to fully replace current mainstays of antidiabetic therapy. Type 2 diabetes is therefore likely to remain an add-on market rather than develop into a switch market.
Reasons to order your copy:
-Understand the key factors that will contribute to the success of the next generation of anti-diabetes drugs
-View independent sales forecasts for products in late stage development for therapy of type 2 diabetes
-Understand physician sentiment on clinical trial endpoints and late-stage candidate drugs for the diabetes market
Customers who bought this item also bought
Pipeline Insight: Non-Insulin Antidiabetics – Incretin Mimetics – Leaders in a Diverse Pipeline
Therapeutic Clinical Intelligence - Type-2 Diabetes Pipeline
Pipeline Insight: Insulin Antidiabetics - Return to Injections - Alternative Delivery Methods Fall by the Wayside
Competitor Analysis: Diabetes Drug Pipeline
Diabetes Drug Discoveries: what the future holds
The World Diabetes Market, 2007-2025: An analysis of Diabetes Drug and Insulin Market
Type 2 Diabetes Market Dynamics: Impact of Januvia and Other DPP-IV Inhibitors
Commercial Insight: Antidiabetics Patent expiries and cost containment initiatives balanced by pipeline products
Diabetes Market Forecast to 2013
Competitor Analysis: GLP-1 Receptor Agonists
U.S. Diabetes Pipeline Outlook
Stakeholder Insight: Diabetes
|
|
|
|
